Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
LNP8701 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
LNP8701 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
LNP8701: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
EMB-09 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
EMB-09 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
EMB-09: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
JWK-007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
JWK-007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
JWK-007: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
AB-303 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
AB-303 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
AB-303: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
PRAK-03202 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
PRAK-03202 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
PRAK-03202: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
FS-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
FS-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
FS-001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Autologous Adipose Derived Stromal Vascular Faction(Mayo Clinic) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Autologous Adipose Derived Stromal Vascular Faction(Mayo Clinic) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Autologous Adipose Derived Stromal Vascular Faction(Mayo Clinic): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensi
Read →
CS-231295 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
CS-231295 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CS-231295: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
CMAB017 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
CMAB017 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CMAB017: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
18F-MNI-654 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
18F-MNI-654 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
18F-MNI-654: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
LCAR-BCX Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
LCAR-BCX Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
LCAR-BCX: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
YK-2168 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
YK-2168 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
YK-2168: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →